About Dutch Colorectal Cancer Group (DCCG)
In The Netherlands an excellent infrastructure exists for the performance of multicentre clinical studies in patients with colorectal cancer. Examples are the TME, PROCTOR, and CAIRO studies. The success of these studies is largely due to the collaboration between the relevant disciplines, such as surgery, radiotherapy, medical oncology, and pathology, as well as the support from data centres such as the regional trial offices of the Comprehensive Cancer Centres. This allows the conduct of large randomized studies with objectives that are relevant to clinical practice in The Netherlands.
The Dutch Colorectal Cancer Group (DCCG) is a collaboration between medical disciplines that are relevant for the diagnosis and treatment of colorectal cancer (surgical oncology, radiotherapy, medical oncology, pathology, radiology, gastroenterology). A member of the National Committee on Guidelines for GI cancer is represented in the board. The primary goal of the DCCG is to initiate clinical scientific research and thereby to promote the quality of diagnosis and treatment of patients with colorectal cancer on a national level.
The DCCG Foundation is registered at the Chamber of Commerce Centraal Gelderland by number 09133996. The DCCG Foundation is registered as ANBI (Algemeen Nut Beogende Instellingen), please click here for more information.
New developments of the DCCG are communicated by newsletters that are sent on a regular basis, as well as during a conference that is held once a year.